Clinical Trials Browser

lenvatinib × Thoracic × 1 year × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

170 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

182 enrolled

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03829332 2026-02-19

LEAP-007

Phase 3 Completed

623 enrolled 26 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04710628 2026-02-19

PECATI

Phase 2 Completed

43 enrolled

Thoracic

Thymoma

NCT03976375 2025-08-15

LEAP-008

Phase 3 Completed

422 enrolled 30 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05078931 2025-07-30

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Phase 2 Active not recruiting

35 enrolled

Thoracic

NSCLC

NCT04924101 2025-07-23

KEYNOTE-B99

Phase 2 Completed

126 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT06318286 2025-05-25

PENINSULA

Phase 2 Recruiting

25 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

Clinical Trials

KEYNOTE-B98

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

LEAP-007

PECATI

LEAP-008

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

KEYNOTE-B99

PENINSULA